

Agenda: Ontario Steering Committee for Cancer Drugs (OSCCD)

Date: June 24, 2019

Time: 1:00-4:00pm

Time	Topic	Description	Presenter (s)
1:00-1:15	<ul style="list-style-type: none">WelcomeAgenda and ObjectivesMOHLTC UpdateCOI DeclarationsWelcome new membersMembership Update	Inform members of current status	Interim Chair MOHLTC
1:15-2:15	<ul style="list-style-type: none">Bendamustine in combination with rituximab for first line treatment of chronic lymphocytic leukemia	Submission	Lead Presenter Clinical Presenter PE Presenter
10 minute BREAK			
2:25-3:25	<ul style="list-style-type: none">Rituximab retreatment for diffuse large b-cell lymphoma	Submission	Lead Presenter Clinical Presenter PE Presenter
3:25-3:55	<ul style="list-style-type: none">Trastuzumab for HER2-positive esophageal adenocarcinoma	Request for Advice	Introduction Clinical Presenter BIA Presenter
3:55-4:00	<ul style="list-style-type: none">Closing remarksReminder to shred materialsHousekeeping Items		Interim Chair